India, April 18 -- According to early clinical trial results shared on Thursday, a new pill may offer blood sugar-lowering and weight-loss effects of injectables like Ozempic and Mounjaro. Eli Lilly's new pill, orforglipron, is also a GLP-1 class of drugs. Also Read | Karan Johar opens up about drastic weight loss, reveals secret behind impressive transformation at 52: It's not Ozempic

Dr Daniel Skovronsky, Lilly's chief scientific officer, told the New York Times, "In the coming decades, more than 700 million people around the world will have Type 2 diabetes, and over a billion will have obesity. Injections cannot be the solution for billions of people around the world."

Unlike the existing GLP-1 drugs, orforglipron is a nonpeptide com...